Cumulative lead exposure and depression and anxiety Statistical Manual of Mental Health Disorders. 4th ed. Washington DC:American Psychiatric Association. Aro ACA, Todd AC, Amarasiriwardena C, Hu H. 1994. Improvements in the calibration of 109Cd K X-ray fluores- cence systems for measuring bone lead in vivo. Phys Med Biol 39(12):2263–2271. Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS. 1995. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med 52(1):2–12. Beekman AT, Copeland JR, Prince MJ. 1999. Review of commu- nity prevalence of depression in later life. Br J Psychiatry 174:307–311. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, Weinstein MC. 1991. Performance of a five-item mental health screening test. Med Care 29(2):169–176. Beusterien KM, Steinwald B, Ware JE Jr. 1996. Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly. J Geriatr Psychiatry Neurol 9(1):13–21. Bjelland I, Krokstad S, Mykletun A, Dahl AA, Tell GS, Tambs K. 2008. Does a higher educational level protect against anxi- ety and depression? The HUNT study. Soc Sci Med 66(6):1334–1345. Boden JM, Fergusson DM. 2011. Alcohol and depression. Addiction 106(5):906–914. Bouchard M, Bellinger DC, Weuve J, Matthews-Bellinger J, Gilman SE, Wright RO, et al. 2009. Blood lead levels and major depressive disorder, panic disorder, and gener- alized anxiety disorder in U.S. young adults. Arch Gen Psychiatry 66(12):1313–1319. Bressler J, Kim KA, Chakraborti T, Goldstein G. 1999. Molecular mechanisms of lead neurotoxicity. Neurochem Res 24(4):595–600. Burger DE, Milder FL, Morsillo PR, Adams BB, Hu H. 1990. Automated bone lead analysis by K-X-ray fluorescence for the clinical environment. Basic Life Sci 55:287–292. Burgess PM, Mazzocco L, Campbell IM. 1987. Discriminant validity of the Crown-Crisp Experiential Index. Br J Med Psychol 60(pt 1):61–69. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. 2010. High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry 67(5):489–496. Colditz GA, Manson JE, Hankinson SE. 1997. The Nurses’ Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6(1):49–62. Cory-Slechta DA, Virgolini MB, Rossi-George A, Thiruchelvam M, Lisek R, Weston D. 2008. Lifetime consequences of com- bined maternal lead and stress. Basic Clin Pharmacol Toxicol 102(2):218–227. Crown S, Crisp AH. 1966. A short clinical diagnostic self-rating scale for psychoneurotic patients: the Middlesex Hospital questionnaire. Br J Psychiatry 112(490):917–923. de Beurs E, Beekman AT, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W. 1999. Consequences of anxiety in older per- sons: its effect on disability, well-being and use of health services. Psychol Med 29(3):583–593. DeVellis RF. 1991. Scale Development: Theory and Applications. London:Sage. Ekong EB, Jaar BG, Weaver VM. 2006. Lead-related nephrotox- icity: a review of the epidemiologic evidence. Kidney Int 70(12):2074–2084. Eum KD, Nie LH, Schwartz J, Vokonas PS, Sparrow D, Hu H, et al. 2011. Prospective cohort study of lead exposure and electrocardiographic conduction disturbances in the Department of Veterans Affairs Normative Aging Study. Environ Health Perspect 119:940–944. Friedman B, Heisel M, Delavan R. 2005. Validity of the SF-36 five-item Mental Health Index for major depression in functionally impaired, community-dwelling elderly patients. J Am Geriatr Soc 53(11):1978–1985. Garza A, Vega R, Soto E. 2006. Cellular mechanisms of lead neurotoxicity. Med Sci Monit 12(3):RA57–RA65. Golub NI, Winters PC, van Wijngaarden E. 2010. A population- based study of blood lead levels in relation to depres- sion in the United States. Int Arch Occup Environ Health 83(7):771–777. Haider S, Shameem S, Ahmed SP, Perveen T, Haleem DJ. 2005. Repeated administration of lead decreases brain 5-HT metabolism and produces memory deficits in rats. Cell Mol Biol Lett 10(4):669–676. Himmelfarb S, Murrell SA. 1984. The prevalence and corre- lates of anxiety symptoms in older adults. J Psychol 116(2d half):159–167. Holmes WC. 1998. A short, psychiatric, case-finding measure for HIV seropositive outpatients: performance characteris- tics of the 5-item mental health subscale of the SF-20 in a male, seropositive sample. Med Care 36(2):237–243. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23(5):477–501. Horwath E, Johnson J, Klerman GL, Weissman MM. 1992. Depressive symptoms as relative and attributable risk fac- tors for first-onset major depression. Arch Gen Psychiatry 49(10):817–823. Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, et al. 1996. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The Normative Aging Study. Am J Epidemiol 144(8):749–759. Jackson LW, Cromer BA, Panneerselvamm A. 2010. Association between bone turnover, micronutrient intake, and blood lead levels in pre- and postmenopausal women, NHANES 1999–2002. Environ Health Perspect 118:1590–1596. Johnson BL, Baker EL, El Batawi M, Gilioli R, Hanninen H, Seppalainen AM, et al. 1987. Prevention of Neurotoxic Illness in Working Populations. Chichester, UK:John Wiley & Sons. Kala SV, Jadhav AL. 1995. Region-specific alterations in dop- amine and serotonin metabolism in brains of rats exposed to low levels of lead. Neurotoxicology 16(2):297–308. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, et al. 1994. Prospective study of phobic anxi- ety and risk of coronary heart disease in men. Circulation 89(5):1992–1997. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005. Lifetime prevalence and age-of-onset dis- tributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6):593–602. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51(1):8–19. Korrick SA, Hunter DJ, Rotnitzky A, Hu H, Speizer FE. 1999. Lead and hypertension in a sample of middle-aged women. Am J Public Health 89(3):330–335. Korrick SA, Schwartz J, Tsaih SW, Hunter DJ, Aro A, Rosner B, et al. 2002. Correlates of bone and blood lead levels among middle-aged and elderly women. Am J Epidemiol 156(4):335–343. Lasley SM, Greenland RD, Minnema DJ, Michaelson IA. 1984. Influence of chronic inorganic lead exposure on regional dopamine and 5-hydroxytryptamine turnover in rat brain. Neurochem Res 9(12):1675–1688. Lyness JM, Kim J, Tang W, Tu X, Conwell Y, King DA, et al. 2007. The clinical significance of subsyndromal depression in older primary care patients. Am J Geriatr Psychiatry 15(3):214–223. Mavissakalian M, Michelson L. 1981. The Middlesex Hospital Questionnaire: a validity study with American psychiatric patients. Br J Psychiatry 139:336–340. National Institute of Mental Health. 2010. NIMH Research Domain Criteria (RDoC). Available: http://www.nimh.nih. gov/research-funding/nimh-research-domain-criteria-rdoc. shtml [accessed 4 March 2011]. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. 2007. Lead exposure and cardiovascular disease—a systematic review. Environ Health Perspect 115:472–482. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. 2002. Postmenopausal hormone replacement therapy: scientific review. JAMA 288(7):872–881. Nie H, Hu H, Chettle DR. 2008. Application and methodology of in vivo K X-ray fluorescence of Pb in bone (impact of KXRF data in the epidemiology of lead toxicity, and con- sistency of the data generated by updated systems). X-ray Spectrom 37(1):69–75. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. 1998. Exposure of the U.S. population to lead, 1991–1994. Environ Health Perspect 106:745–750. Rajan P, Kelsey KT, Schwartz JD, Bellinger DC, Weuve J, Sparrow D, et al. 2007. Lead burden and psychiatric symp- toms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. Am J Epidemiol 166(12):1400–1408. Rhodes D, Spiro A III, Aro A, Hu H. 2003. Relationship of bone and blood lead levels to psychiatric symptoms: the Normative Aging Study. J Occup Environ Med 45(11):1144–1151. Schwartz BS, Lee BK, Bandeen-Roche K, Stewart W, Bolla K, Links J, et al. 2005. Occupational lead exposure and longitu- dinal decline in neurobehavioral test scores. Epidemiology 16(1):106–113. Seeman E. 2003. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporo- sis. Osteoporos Int 14(suppl 3):S2–S8. Shih RA, Hu H, Weisskopf MG, Schwartz BS. 2007. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect 115:483–492. Simon G, Ormel J, VonKorff M, Barlow W. 1995. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 152(3):352–357. Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, et al. 2000. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 57(6):601–607. Theppeang K, Glass TA, Bandeen-Roche K, Todd AC, Rohde CA, Schwartz BS. 2008. Gender and race/ethnicity differences in lead dose biomarkers. Am J Public Health 98(7):1248–1255. van’t Veer-Tazelaar PJ, van Marwijk HW, van Oppen P, van Hout HP, van der Horst HE, Cuijpers P, et al. 2009. Stepped-care prevention of anxiety and depression in late life: a randomized controlled trial. Arch Gen Psychiatry 66(3):297–304. Vink D, Aartsen MJ, Schoevers RA. 2008. Risk factors for anxi- ety and depression in the elderly: a review. J Affect Disord 106(1–2):29–44. Virgolini MB, Chen K, Weston DD, Bauter MR, Cory-Slechta DA. 2005. Interactions of chronic lead exposure and inter- mittent stress: consequences for brain catecholamine systems and associated behaviors and HPA axis function. Toxicol Sci 87(2):469–482. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R, et al. 2009. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 66(6):617–626. Ware J, Kosinksi M, Dewey J. 2000. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI:Quality Metric Inc. Ware JE Jr, Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. 2003. Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov Disord 18(6):646–651. Weisskopf MG, Jain N, Nie H, Sparrow D, Vokonas P, Schwartz J, et al. 2009. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation 120(12):1056–1064. Werner FM, Covenas R. 2010. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 120(7):455–470. Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, et al. 2009. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses’ Health Study. J Am Coll Cardiol 53(11):950–958. WHO (World Health Organization). 2001. The World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva:WHO. Wiesbeck GA, Kuhl HC, Yaldizli O, Wurst FM, WHO/ISBRA Study Group on Biological State and Trait Markers of Alcohol Use and Dependence. 2008. Tobacco smoking and depression— results from the WHO/ISBRA study. Neuropsychobiology 57(1–2):26–31. Wilker E, Korrick S, Nie LH, Sparrow D, Vokonas P, Coull B, et al. 2011. Longitudinal changes in bone lead levels: the VA Normative Aging Study. J Occup Environ Med 53(8):850–855. Wu LJ, Kim SS, Zhuo M. 2008. Molecular targets of anxiety: from membrane to nucleus. Neurochem Res 33(10):1925–1932. Environmental Health Perspectives • volume 120 | number 6 | June 2012 823